Biogen/Elan hope updated Tysabri label will lend confidence to patients/prescribers
This article was originally published in Scrip
The EC has approved the inclusion of anti-JC virus (JCV) antibody status to Biogen Idec/Elan's Tysabri (natalizumab) label "to aid in stratifying patients at risk for developing progressive multifocal leukoencephalopathy (PML)". Long-term growth potential of Tysabri could be dependent on patient risk stratification for PML, but it not yet clear what proportion of potential Tysabri patents would be tested for JCV status.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.